Pull to refresh
Logo
What Changed
Following Why Sign Up
Bacteria use a virus's own enzyme as an immune alarm

Bacteria use a virus's own enzyme as an immune alarm

New Capabilities

Discovery explains how the CBASS immune pathway detects phage infection; a large-scale screen confirms the mechanism, and a separate report describes a different self-destruct defense.

October 31st, 2026: Separate bacterial defense reported to work in reverse

Overview

Updated Nov 1

Bacteria have a last-resort defense against viruses: an infected cell kills itself before the virus can spread. Research published October 1 in Science shows the virus's own enzyme sets off that switch.

The trigger is a phage protease, an enzyme the virus uses during infection. When it cuts a bacterial sensor, the cell's CBASS pathway (cyclic oligonucleotide-based antiphage signaling) fires. A screen of 975 bacteria-phage pairings confirmed the trigger and showed phages can escape it by mutating shell-assembly proteins. On October 31, ScienceDaily reported a separate bacterial defense that switches on its toxin only after infection begins.

Why it matters

If phages can be engineered around bacterial immune alarms, phage therapy becomes a more reliable weapon against antibiotic-resistant infections.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

3
CD-NTase clades with identified activation loops
Clades A, D, and G of the CD-NTase enzyme family carry the protease-cleavable activation loop.
975
Bacteria-phage pairings screened
A large-scale Type I CBASS screen confirmed the prohead protease mechanism and mapped how phages evade it.
3
Phage antidefense protein families identified
Sequestin, Lockin and Acb5 block bacterial immune signals; Acb5 cleaves the CBASS signal molecule 3'3'-cGAMP.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

SH
Sam Hobbs
Lead researcher, University of Utah Health
Lead author of the Science paper on CBASS activation
 Philip J. Kranzusch
Philip J. Kranzusch
Co-author of the Science paper
Co-discoverer of the CBASS activation mechanism

Organizations Involved

University of Utah Health
University of Utah Health
Academic health system
Research institution where the discovery was made

University of Utah Health is the academic medical center where Sam Hobbs conducted the research.
Science Magazine
Science Magazine
Scientific journal and news outlet
Published the research

Science, the peer-reviewed journal published by the American Association for the Advancement of Science, ran the October 1, 2026 paper.

Timeline

2026 October 2026

4 events Latest: October 31st, 2026 · 1 week ago
Tap a bar to jump to that date

  1. Separate bacterial defense reported to work in reverse

    Latest Publication

    ScienceDaily reported a bacterial defense that makes the DNA for its lethal weapon only after infection starts, unlike systems that hold a toxin in check. The report does not describe this system as CBASS.

  2. University of Utah Health announces the discovery

    Announcement

    The university publicizes the finding that a viral enzyme cutting a bacterial sensor protein triggers a self-destructing immune response.

  3. Science publishes CBASS activation paper

    Publication

    Hobbs and Kranzusch publish findings showing phage prohead proteases activate CBASS immunity by cleaving CD-NTase enzymes.

  4. Large-scale CBASS screen maps immune evasion

    Publication

    A separate study screened 975 Type I CBASS bacteria-phage pairings and confirmed the phage prohead protease as a key trigger. It also showed phages evade CBASS by mutating virion assembly proteins.

Scenarios

1

Phage therapy engineered to bypass CBASS enters clinical trials

Possible Resolves by End of 2028

Discussed by: University of Utah Health researchers and phage therapy developers

The discovery identifies the exact protease cleavage site on CD-NTase enzymes. Researchers could engineer therapeutic phages that avoid triggering CBASS, making phage therapy more reliable against antibiotic-resistant bacteria. This would require modifying phage prohead proteases or the phage genome to evade detection.

2

Researchers map CBASS activation across more phage families

Likely Resolves by End of 2027

Discussed by: Hobbs and colleagues; the Science paper notes cleavable enzymes in a range of bacteria

The current study identified activation loops in clade A, D, and G CD-NTases and showed recognition of phage T4. Follow-up work could map how other phage families trigger CBASS, revealing the full range of viral threats bacteria can detect through protease activity.

3

Protease-triggered immune activation found in human cells

Unlikely Resolves by End of 2028

Discussed by: Hobbs, who noted CBASS is related to human immune pathways

CBASS is evolutionarily related to cGAS-STING in humans. The finding that proteases can trigger immune signaling in bacteria raises the question of whether similar protease-based detection exists in human innate immunity. This would require demonstrating that a human protease cleaves a cGAS-STING pathway component to activate signaling.

4

Phage antidefense proteins become a design lever for therapeutic viruses

Possible Resolves by End of 2027

Discussed by: Authors of a Science study on phage proteins that block bacterial immune signaling

Phages carry proteins that break down or absorb the nucleotide signals bacterial immune systems make. One, Acb5, cleaves the CBASS signal molecule 3'3'-cGAMP; the others, Sequestin and Lockin, bind signals from a different system, Thoeris. If these proteins can be added or removed deliberately, researchers could tune whether a therapeutic phage trips CBASS or slips past it.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2012

CRISPR-Cas9 discovery (2012)

Researchers discovered that CRISPR-Cas9, a bacterial adaptive immune system that cuts viral DNA, could be programmed to edit any DNA sequence. Jennifer Doudna, Emmanuelle Charpentier, and colleagues published the foundational work.

Then

Within years, CRISPR became the standard tool for gene editing in labs worldwide.

Now

Doudna and Charpentier won the 2020 Nobel Prize in Chemistry. CRISPR-based therapies are now in clinical trials.

Why this matters now

Like CRISPR, CBASS is a bacterial immune system whose study could yield powerful biotechnology tools. Understanding how bacteria detect phages could improve phage therapy.

2012-2013

cGAS-STING pathway discovery (2012-2013)

Scientists identified cGAS as the cytosolic DNA sensor that activates STING, triggering innate immune responses. This pathway is the human counterpart to CBASS.

Then

The discovery explained how cells detect DNA in the cytoplasm and launched a wave of research into innate immunity.

Now

cGAS-STING is now a major drug target for cancer immunotherapy and autoimmune disease.

Why this matters now

CBASS is evolutionarily related to cGAS-STING. The new finding that proteases activate CBASS raises questions about whether similar mechanisms exist in human immunity.

Sources

(11)
+5
ScienceDaily Science @theU (University of Utah) Phys.org EurekAlert! Genetic Engineering & Biotechnology News Nature Reviews Microbiology SciBeat PMC (PubMed Central) Science ScienceDaily